Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 1/20 | 0.63 |
| ▸ | POLB | P06746 | 2/20 | 0.52 |
| ▸ | PYGM | P11217 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | RECQL | P46063 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30567101 | 1.00 | MTNR1B (0.63) | MTNR1BPOLBPYGMALDH1A1KDM4E | |
| SCHEMBL18666149 | 0.92 | ALDH1A1 (0.55) | MTNR1BPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL31120712 | 0.91 | MTNR1B (0.53) | MTNR1BPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL31522175 | 0.90 | MTNR1B (0.56) | MTNR1BPOLBPYGMALDH1A1KDM4E | |
| SCHEMBL18666146 | 0.89 | ADRA2C (0.54) | MTNR1BPOLBALDH1A1LMNATDP1 | |
| SCHEMBL29660113 | 0.89 | ADRA2C (0.54) | MTNR1BPOLBALDH1A1LMNATDP1 | |
| SCHEMBL18666150 | 0.89 | MTNR1B (0.47) | MTNR1BALDH1A1KDM4EMAPTRECQL | |
| SCHEMBL25388461 | 0.88 | MTNR1B (0.62) | MTNR1BPOLBPYGMALDH1A1LMNA | |
| SCHEMBL31060099 | 0.88 | MTNR1B (0.48) | MTNR1BPOLBALDH1A1KDM4ELMNA | |
| SCHEMBL31120716 | 0.87 | MTNR1B (0.47) | MTNR1BALDH1A1TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171404-A1 | PCNA INHIBITORS AND USES THEREOF | UNITED STATES GOVERNMENT | 2025-05-29 | — | — | US | disclosed |
| WO-2023172880-A2 | PCNA INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2023172880-A2 | PCNA INHIBITORS AND USES THEREOF | CITY OF HOPE (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2022232509-A1 | PCNA INHIBITORS AND EGFR INHIBITORS FOR CANCER TREATMENT | CITY OF HOPE (US) | 2022-11-03 | — | — | WO | disclosed |
| US-11345656-B2 | PCNA inhibitors | CITY OF HOPE (US) | 2022-05-31 | — | — | US | disclosed |
| US-20210078938-A1 | PCNA INHIBITORS | THE GOVERNMENT OF THE UNITED STATES AS REPRESENTED BY THE SECRETARY OF THE ARMY | 2021-03-18 | — | — | US | disclosed |
| US-10913706-B2 | PCNA inhibitors | CITY OF HOPE (US) | 2021-02-09 | — | — | US | disclosed |
| US-20200216386-A1 | PCNA INHIBITORS | UNITED STATES GOVERNMENT | 2020-07-09 | — | — | US | disclosed |
| US-10550070-B2 | PCNA inhibitors | CITY OF HOPE (US) | 2020-02-04 | — | — | US | disclosed |
| WO-2017049206-A1 | PCNA INHIBITORS | CITY OF HOPE (US) | 2017-03-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10913706-B2 | PCNA inhibitors | PCNA, MKI67, PCLAF | MTNR1B 4447/4885POLB 28/4885PYGM 3670/4885 |
| US-20210078938-A1 | PCNA INHIBITORS | PCNA, MKI67, PCLAF | MTNR1B 4447/4885POLB 28/4885PYGM 3670/4885 |
| US-11345656-B2 | PCNA inhibitors | PCNA, MKI67, PCLAF | MTNR1B 4447/4885POLB 28/4885PYGM 3670/4885 |
| US-10550070-B2 | PCNA inhibitors | PCNA, MKI67, PCLAF | MTNR1B 4447/4885POLB 28/4885PYGM 3670/4885 |
| US-20200216386-A1 | PCNA INHIBITORS | PCNA, MKI67, PCLAF | MTNR1B 4447/4885POLB 28/4885PYGM 3670/4885 |
| US-20250171404-A1 | PCNA INHIBITORS AND USES THEREOF | PCNA, MKI67, PCLAF | MTNR1B 4532/4885POLB 23/4885PYGM 2611/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.